Recent study has indicated that cocaine-amphetamine-regulated transcript (CART) is an anorectic chemical in the brain. In the present study, we examined the hypothesis that CART may act in the central nervous system to alter gastric function. Food consumption, gastric acid secretion, and gastric emptying were measured after injection of CART into the cerebrospinal fluid in 24-h fasted Sprague Dawley rats. Central injection of CART inhibited food intake, gastric acid secretion, and gastric emptying. In contrast, ip injection of CART failed to inhibit gastric acid secretion and gastric emptying, suggesting that CART acts in the brain to suppress gastric acid secretion and gastric emptying. In the vagotomized animals, centrally administered CART did inhibit pentagastrin-stimulated gastric acid secretion. The CARTinduced acid inhibition was also observed in rats treated with indomethacin, a cyclooxygenase inhibitor. In contrast, pretreatment with central administration of a CRF receptor antagonist, ␣-helical CRF9 -41, completely blocked the central CART-induced inhibition of gastric acid secretion. All these results suggest that CART acts in the brain to inhibit gastric function via brain CRF system. The vagal pathway and the prostaglandin system are not involved in the acid inhibition.
C OCAINE-AMPHETAMINE-REGULATED transcript
(CART) messenger RNA (mRNA) was isolated from rat brain striatum by PCR differential display as an mRNA transcriptionally regulated by acute administration of cocaine or amphetamine (1) . CART mRNA is expressed in several areas throughout the rat and human brain as well as in the rat anterior pituitary and adrenal medulla (1) . In the brain, CART mRNA is highly expressed within hypothalamic structures implicated in the central control of feeding behavior and metabolism, i.e. the paraventricular, arcuate, and dorsomedial hypothalamic nuclei and the lateral hypothalamus (1) . The distribution of CART peptide immunoreactivity in the hypothalamus has been mapped using antibodies generated against synthetic fragments of CART (2, 3) , or a CART fusion protein (4) and shows an almost perfect overlap of CART immunoreactive cell bodies and CART mRNA.
With regard to the pathophysiological relevance of CART in the brain, Kristensen et al. (4) raised a hypothesis that CART is a new anorectic peptide because intracerebroventricular administration of CART (55-102) potently inhibits food intake and fasting reduces the expression of CART mRNA in the arcuate nucleus. Lambert et al. also showed that centrally injected CART peptide fragments significantly suppressed feeding (5) . In fa/fa rats and ob/ob mice, the CART mRNA is virtually absent from the arcuate nucleus and in ob/ob mice the expression is increased upon leptin treatment (4) . These results suggest that leptin-induced anorexia may be mediated by brain CART. Based upon these evidences, endogenous CART may be one of the regulatory peptides that play a physiological role in the control of feeding behavior.
However, we do not know yet at this moment a physiological relevance of CART in body functions other than the regulation of feeding behavior. CART neurons are distributed in the paraventricular hypothalamic nucleus, the dorsomedial hypothalamic nucleus, and the lateral hypothalamic nucleus (2, 3) . These hypothalamic nuclei are involved in not only regulation of feeding but control of gut function (6) . In the present study, we made a hypothesis that CART may act in the brain to regulate gastric functions.
Materials and Methods Animals
Male Sprague Dawley rats weighing approximately 200 g were housed under controlled light/dark conditions (lights on: 0700 -1900 h) with the room temperature regulated to 23-25 C. Rats were allowed free access to standard rat chow (Solid rat chow, Oriental Yeast Co., Tokyo, Japan) and tap water. All experiments were performed in conscious animals deprived of food for 24 h but with free access to water up to the initiation of the experiments. Deprivation of food might be favorable to the present study because fasting could minimize endogenous CART expression (4) . In the experiments to examine the effect of CART on gastric acid secretion and gastric emptying, no food was available during the experiments.
food intake because intracerebroventricular injection of the CART (55-102) peptide potently inhibits food intake (4). The peptide corresponding to CART (55-102) was identified in ovine hypothalamic extracts during the isolation of somatostatin-like peptide (7) . It is therefore speculated that the C-terminal CART could be an endogenous peptide that corresponds to a naturally occurring form of CART. Synthetic rat CART (55-102) was purchased from Peptide Institute Inc., Osaka, Japan and was dissolved in normal saline just before experiments. Indomethacin (Sigma, St. Louis, MO) was dissolved in a vehicle (7.5% sodium bicarbonate solution). A CRF antagonist, ␣-helical CRF9 -41, and pentagastrin was purchased from Peninsula Laboratories, Inc. (St. Helens, UK) and was dissolved in normal saline just before experiments.
Measurement of food intake
Evaluation of food consumption was done as described previously (8) . Each rat was transferred to a individual metabolic cage 1 day before the experimental procedures and kept isolated throughout the experiments. This experiment was performed in 15 animals deprived of food for 24 h but with free access to water. Twenty-four-hour-fasted rats received intracisternal injection of CART or saline in a volume of 10 l.
Intracisternal injection is defined as an administration of a solution into the cisterna magna. Intracisternal injections were performed acutely under short ether anesthesia (ϳ2 min) by puncture of the occipital membrane with a 10-l-Hamilton microsyringe after rats were mounted in a stereotaxic apparatus (David Kopf Instruments, Tijunga, CA). The presence of cerebrospinal fluid in the Hamilton syringe upon aspiration before injection insured correctness of needle placement into the cisterna magna. Immediately after the intracisternal injection, rats were returned to their cages, and preweighted rat chow was given to each rat and the weight of uneaten food was measured every 1 h for 8 h.
Measurement of gastric secretion
Gastric secretion was measured using the pylorus-ligation method as described previously (9) . Rats received intracisternal injection of 1, 2, or 4 g of CART or saline. Intracisternal injection was performed as described above. Following the intracisternal injection and ligation of the pylorus under brief ether anesthesia (ϳ5 min), rats were returned to their cages. Four or 8 h after the treatment, rats were killed by overdose of ether. The stomachs were removed, and the gastric content were collected and centrifuged. The volume of gastric secretion was measured and the amount of gastric acid was determined by titration with 0.01 n NaOH to a pH of 7.0. The unit of gastric acid output is equivalent (Eq). Ip injection of 4 g of CART dissolved in 0.5 ml of saline was performed to examine the possibility that centrally administered CART was acting periphery by leaking into the circulation. As a control, normal saline (0.5 ml) alone was injected ip under short ether anesthesia. In the experiment to examine the time-course effect of CART on gastric acid secretion, rats received intracisternal injection of 4 g dose of CART or saline, and gastric secretion was measured 4 or 8 h after the injection.
To investigate the role of the vagus nerve in inhibition of gastric acid secretion by central CART, rats underwent bilateral gastric branch vagotomy as described previously (10) . Briefly, under ether anesthesia (approximately 5 min), a ventral abdominal incision was made along the midline, and the liver was cranially and laterally retraced to expose the right and left gastric branches of the vagus nerve along the abdominal esophagus, which were identified under an operative microscope. Both nerves were separated and freed for a length of 3 mm from the esophagus at a site immediately rostral to the esophagogastric junction and then cut. CART in a dose of 2 g or saline was administered intracisternally in vagotomized rats with or without ip injection of 75 g/kg pentagastrin. Background stimulation with pentagastrin was used because gastric acid output in vagotomized rats is very low, which would mask the inhibitory action of CART. The dose of pentagastrin was according to a previous publication (10) . Immediately after the treatments, the pylorus was ligated. These procedures including vagotomy were performed under ether anesthesia within 10 min. Two hours after the treatment, gastric contents were collected and gastric acid output was measured as described above.
To test the hypothesis that prostaglandins are involved in central CART-induced acid inhibition, we examined the effect of indomethacin, a prostaglandin synthesis inhibitor, on the acid inhibition by intracisternal injection of CART. Indomethacin at a dose of 10 mg/kg was administered sc 60 min before CART injection at a dose of 2 g and pylorus ligation. The dose of indomethacin was selected as described previously (10) . Four hours after the treatment, gastric contents were collected and gastric acid output was measured as described above.
The possibility that CRF, a neuropeptide that inhibits acid secretion through the central action, may mediate the CART-induced acid inhibition was evaluated. To address the problem, ␣-helical CRF9 -41, an antagonist for CRF (11) , was used to block the action of endogenous CRF in the brain. After brief ether anesthesia, pylorus-ligated rats received intracisternal administration of ␣-helical CRF9 -41 (10 g/5 l) or saline (5 l) together with CART (2 g/5 l) or saline (5 l), and gastric acid secretion was measured 4 h after the treatment as described above. The dose (10 g) of ␣-helical CRF9 -41 used in this study was selected according to a previous publication (12) .
Measurements of gastric emptying
Gastric emptying was measured using a modification of the phenol red method which has been published previously (13) . The test meal consisted of a solution of 50 mg phenol red dissolved in 100 ml aqueous methylcellulose (1.5%, wt/vol). This liquid meal was given by oral intubation in an amount of 1.5 ml/rat under brief ether anesthesia.
Sixty minutes after the test meal, the animals were killed by overdose of ether to collect the gastric contents to measure gastric emptying. Under brief ether anesthesia, rats received intracisternal injection of 1, 2, or 4 g of CART. Immediately after the injection of CART, the test meal was administered into the stomach. Sixty minutes after the test solution, the animals were killed and the stomach was removed to measure the rate of gastric emptying. Four rats were killed immediately after the meal intubation, the gastric content of phenol red contents determined, and these calculations were used as zero emptying point. To measure the gastric contents, the stomach was exposed by laparotomy, quickly ligated at the pylorus and the esophago-gastric junction and then removed. The stomach and its contents were homogenized in 40 ml of 0.1 m NaOH and phenol red content determined using methods described elsewhere (13) . Briefly, this assay involves precipitation of proteins with 20% trichloroacetic acid, alkalization with 0.5 m NaOH, and a colorimetric assay at 560 nm. Gastric emptying was calculated according to the following formula (PR, phenol red):
Gastric emptying ͑%͒ ϭ ͩ 1 Ϫ amount of PR recovered from a test stomach average amount of PR recovered from standard stomachs ͪ ϫ 100
The amount of phenol red recovered from the stomachs of rats killed immediately after the intragastric delivery of the meal served to determined the zero emptying point.
Statistical analysis
The results are expressed as mean Ϯ sem. Statistical analysis was performed by ANOVA and subsequent Fisher's LSD test. P Ͻ 0.05 was considered statistically significant.
Ethical considerations
Experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by the Public Health Service. The approval of the Research and Development and Animal Care committees at the Asahikawa Medical College was obtained for all studies.
Results
First, we examined the effects of intracisternal injection of CART on feeding behavior. As shown in Fig. 1 , centrally administered CART in a dose of 1 g significantly inhibited food consumption for 3 h. Furthermore, 2 g dose of CART injected into the cisterna magna potently suppressed food intake up to 8 h after injection. The inhibitory action of CART on feeding was dose dependent. These results confirmed that CART acts in the brain to suppress food intake.
Next, we examined the effect of central CART on gastric acid secretion. Figure 2 illustrates the effects of intracisternal injection of CART on gastric secretion in pylorus-ligated conscious rats. A 1-g dose of CART did not alter gastric secretion. However, a 2-or 4-g dose of CART significantly reduced the volume of gastric juice and inhibited gastric acid output ( Fig. 2A) . Volume of gastric juice and acid output were inhibited by central CART in a parallel fashion. In contrast, ip administration of CART in a dose of 4 g failed to inhibit acid secretion (Table 1 ). Figure 2B illustrates the time-course effects of intracisternal CART on gastric secretion. Gastric secretion was still inhibited 8 h after the central injection of CART, indicating that the acid inhibitory action of CART was long-lasting.
To evaluate whether central CART-induced inhibition of gastric secretion is mediated by the vagal system, we examined the effects of surgical vagotomy on the CART-induced inhibition of gastric acid secretion. Figure 3 illustrated the effect of vagotomy on the CART-induced inhibition of acid secretion. Vagotomy by itself potently inhibited gastric acid secretion when compared with vagus-intact animals as shown in Fig. 2 . In the vagotomized rats, intracisternal injection of CART did not significantly suppress acid secretion. The lack of inhibition of acid secretion may be due to the low baseline of acid secretion in the vagotomized animals. We therefore next increased the acid baseline by ip administration of pentagastrin in vagotomized animals and examined the effects of intracisternal injection of CART on gastrinstimulated gastric secretion. In this condition, intracisternal CART significantly inhibited gastric acid secretion.
Next, we examined the possibility that endogenous prostaglandins are implicated in the CART-induced acid inhibition. Figure 4 illustrates the effect of indomethacin, a cyclooxygenase inhibitor, on the CART-induced inhibition of gastric acid. In saline-treated control rats, intracisternal injection of CART in a dose of 2 g significantly inhibited gastric acid secretion. Similarly, intracisternal CART suppressed acid production in rats pretreated with indomethacin. Figure 5 demonstrates the role of endogenous brain CRF in the CART-induced acid inhibition. In saline-treated control rats, intracisternal CART significantly inhibited gastric acid secretion. ␣-helical CRF9 -41, an antagonist for CRF, by itself did not change gastric acid secretion, being in agreement with previous reports (12, 14) . Injection of CART into the cisterna magna failed to inhibit gastric acid secretion in rats treated with ␣-helical CRF9 -41. Figure 6 shows the effects of intracisternal administration of CART on gastric emptying. Centrally injected CART dosedependently delayed the rate of gastric emptying. The significant inhibition of gastric emptying was obtained by a 2-g dose of CART. However, suppression of gastric emptying could not be found after ip injection of CART ( Table 2 ), indicating that CART acts centrally in the brain to suppress gastric emptying.
Discussion
The present study first confirmed that centrally administered CART potently suppressed feeding in a dose-dependent manner. In the present study, we injected CART into the cisterna magna, whereas intracerebroventricular injection The animals were killed 4 h after intraperitoneal injection of saline or CART. Each value represents the mean Ϯ SEM of the indicated number of animals. FIG. 3 . Effect of vagotomy on the acid inhibition by intracisternal injection of CART in pylorus-ligated rats. Under brief ether anesthesia, bilateral gastric branch vagotomy was performed. Vagotomized rats were given an intracisternal injection of CART. Then pentagastrin or saline was administered ip, and the pylorus was ligated. Four hours after pylorus ligation, the animals were killed and the stomach was removed. The volume was measured and gastric acid output was determined. Each point represents the mean Ϯ SEM of 5 animals. * P Ͻ 0.01, when compared with saline (gastrin).
FIG. 4. Effect of indomethacin on the acid inhibition by intracisternal
injection of CART in pylorus-ligated conscious rats. Under brief ether anesthesia, rats were administered indomethacin (10 mg/kg) or vehicle, sc. One hour after indomethacin injection, rats received intracisternal injection of CART or saline and the pylorus was ligated. Four hours after pylorus ligation, the animals were killed, and the stomach was removed. The volume was measured and gastric acid output was determined. Each point represents the mean Ϯ SEM of 5 animals. *, P Ͻ 0.01, when compared with saline (indomethacin).
was performed in the previous studies (4, 15) . The doseresponse effects of CART on food consumption by using intracisternal or intracerebroventricular route is quiet similar, suggesting that intracisternal route is good enough to evaluate the effect of CART on the brain. The major findings in this study were that intracisternal injection of CART potently inhibited gastric acid secretion and gastric emptying. These observations together with a lack of inhibition of gastric acid secretion and gastric emptying by peripheral administration of CART indicate that CART may act in the central nervous system to inhibit gastric acid secretion and gastric emptying. It would be therefore suggested that CART should be listed as a novel peptide in the brain to regulate gastric functions.
The dose of CART to achieve a significant inhibition of gastric acid output and gastric emptying was 2 g/rat. Almost same dose range of CART inhibited food consumption and gastric function. According to the previous findings, intracerevroventricular CART in doses of 1 and 2 g/rat inhibited food consumption and anti-CART antibody increased feeding (4, 15) . In addition, fasting down-regulated CART mRNA in the hypothalamus (4). These results strongly suggest that endogenous CART plays a role in the central control of feeding behavior. Considering this evidence, the present observation that the inhibition of gastric acid secretion and gastric emptying was observed by the same dose range of CART to inhibit feeding may suggest that suppression of gastric acid and gastric emptying might occur at a physiological concentration of CART. However, we cannot be sure that intracisternal injection of CART resulted in local brain concentrations that might normally be present in a rat.
Intracisternal injection of CART dose-dependently inhibited food intake and gastric emptying. In contrast, a dosedependent action was not clearly found in the CARTinduced acid inhibition. We do not know at this moment the reason why dose-response of gastric acid secretion was not clearly observed in rats treated with central injection of CART. The lack of dose-dependent inhibition of acid secretion by CART in the present study might be due to a relatively small number of animals or the time period tested. Otherwise, more than 4 g dose of CART might be needed for further inhibition of acid secretion.
So far, a number of neuropeptides and chemicals have been examined to have a role in the central control of feeding behavior. It is of interest that majority of neuropeptides or chemicals that influence feeding also contribute to the central regulation of gastrointestinal function. These include CRF (16, 17) , interleukin-1 ␤ (18, 19, 20) , basic fibroblast growth factor (21, 22, 23) , apolipoprotein A-IV (9, 10, 13, 24), and orexins (25, 26) . The present observation that centrally administered CART inhibited not only food intake but also gastric acid and gastric emptying, furthermore supporting our hypothesis that a anorectic/orexigenic chemical may be involved in central control of gut function. Under brief ether anesthesia, rats received intracisternal injection of several doses of CART. Immediately after the central injection, the animals were given test meal. One hour later, the animals were killed and the stomach was removed to measure gastric emptying. Each column represents the mean Ϯ SEM of 5 animals. *, P Ͻ 0.05, when compared with saline (CART, 0). Under brief ether anesthesia, rats were injected with saline or CART (2 g) ip. Immediately after the ip injection, test meal was given by oral intubation. One hour later, rats were killed to determine the rate of gastric emptying. Each value represents the mean Ϯ SEM.
The present study clearly demonstrated that CART acts in the brain to delay gastric emptying. The delayed gastric emptying by CART might provide a mechanism by which CART has an anorectic action because appetite is likely to be lost when the stomach remains filled. Broberger et al. (27) have very recently demonstrated the presence of CART in the rat vagus nerve and nodosa ganglion (n.g.). This neuroanatomical evidence suggests that CART in the vagal afferent fibers may transmit visceral sensation such as gastric distention from the stomach to the brain stem. The present observation that CART may act in the brain to suppress gastric emptying indicates that CART acts as an efferent signal from the brain to the stomach. In this case, the source of CART may be in the hypothalamus. We cannot, however, exclude the possibility that CART originated in the n.g. may act in the brain to inhibit gastric function. In the latter case, CART may function as a chemical messenger to regulate gastric functions controlled by visceral sensation through the vagal afferent fibers from the stomach.
The vagus nerve is one of the final common pathways that transmit centrally integrated output from the brain to the stomach in the regulation of gastric acid secretion (6) . We therefore examined a role of the vagal system in the inhibition of gastric acid secretion by central CART using surgically vagotomized rats. Gastrin-stimulated acid secretion in vagotomized rats is a different model when compared with the pylorus-ligation alone. However, there is no way other than the present procedures to examine a role of the vagus nerve in the central CART-induced acid inhibition. So far, a couple of studies have been done using a gastrin-stimulated gastric secretion model with pylorus-ligation in vagotomized rats to clarify that centrally applied chemicals inhibited gastric secretion in a vagal-dependent or independent manner (10, 28) . We therefore examined the effect of intracisternal injection of CART on pentagastrin-stimulated gastric acid secretion in vagotomized rats. In the vagotomized animals, intracisternal CART did inhibit the gastrin-stimulated gastric acid secretion, suggesting that the vagus nerve dose not mediate the central CART-induced inhibition of gastric acid secretion.
It has been reported that central prostaglandin E 2 is involved in the regulation of acid secretion. Centrally administered prostaglandin E 2 inhibited gastric acid secretion (29, 30) , and central (400 g) or peripheral (10 mg/kg) administration of indomethacin reverses the inhibitory action of neuropeptides and cytokines on gastric secretion. These include dermorphin, calcitonin gene related peptide and interleukin-1 (19, 31) . The dose of indomethacin (10 mg/kg) used in this study is known to suppress prostaglandin synthesis both in the brain and the stomach (29) . Although it is not known whether central CART is involved in the metabolism of prostaglandins, we tested the hypothesis that prostaglandins are involved in the CART-induced inhibition of gastric acid secretion. The present finding that centrally injected CART significantly suppressed acid secretion in rats pretreated with indomethacin excludes the prostaglandin pathway in the mechanism of action of CART.
CRF in the brain plays a role in the regulation of gastric acid secretion. For example, intracisternal injection of CRF inhibits gastric acid secretion in rats (17) . CRF injected into the cerebrospinal fluid mimics the effects of various stressors on gastric acid secretion in rats (32, 33) . It is furthermore demonstrated that the CRF antagonist, ␣-helical CRF9 -41, injected into the cerebrospinal fluid prevents stress-induced alternation of gastric secretion (14, 34) . Thus, brain CRF plays a role in mediating stress-induced alternation of gastric secretory function. Considering these evidence, we tested a hypothesis that CRF in the brain may mediate the CARTinduced inhibition of gastric acid secretion. The present result indicates that the CART-induced inhibition of gastric acid secretion was completely blocked by ␣-helical CRF9 -41. This evidence suggests that endogenous CRF in the brain mediates the CART-induced acid inhibition. The CARTinduced inhibition of acid did not depend on the vagal system because of a persistence of acid inhibition by central injection of CART in vagotomized animals as demonstrated in this study. Previous studies demonstrated that CRF in the brain exerts its inhibitory action on gastric secretion via a vagus independent pathway (12, 35) . This evidence may furthermore support our hypothesis that CRF in the brain mediates the CART-induced acid inhibition through a vagusindependent pathway.
Vrang et al. (15) have injected CART into the cerebrospinal fluid in rats and examined its effect on c-fos expression in the brain. According to their data, CART induced c-fos expression in several hypothalamic and brain stem structures. In the hypothalamus, high number of c-fos immunoreactive cells were observed in the paraventricular nucleus of the hypothalamus (PVN) and in the posterior part of the dorsomedial hypothalamic nucleus. It has been shown that CRF neurons are distributed mainly in the PVN (36 -38) . In fact, c-fos positive elements in the PVN seen after CART injection were observed in the area where most of the CRF containing neurons are located (15) . This evidence led us to speculate that centrally administered CART activates neurons in the PVN that contain CRF. This speculation may explain the mechanism by which CART acts in the brain to inhibit acid secretion through endogenous CRF. In other words, we suggest that CART acts in the CRF-containing neurons in the PVN, and then released CRF inhibits gastric acid secretion through a vagus-independent mechanism.
In summary, the present study suggests for the first time that CART may act in the brain to inhibit not only feeding but gastric function such as gastric acid secretion and gastric emptying. Endogenous CRF in the brain may mediate the acid inhibition by CART.
